FDA's supplemental NDA reviews
Executive Summary
The backlog of efficacy supplements exceeding FDA's statutory review time has decreased from 169 to 113 since last March, FDA Office of Drug Research & Review Director Robert Temple, MD, noted at a Nov. 24 press briefing. "The Pink Sheet" (Dec. 1, p. 8) did not specify that the reduction referred specifically to efficacy supplements.